Literature DB >> 11764079

Value of CD23 determination by flow cytometry in differentiating mantle cell lymphoma from chronic lymphocytic leukemia/small lymphocytic lymphoma.

J Z Gong1, A S Lagoo, D Peters, J Horvatinovich, P Benz, P J Buckley.   

Abstract

Mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) share many morphologic and immunophenotypic features. In addition to histomorphologic examination, it is customary to use the absence of CD23 to differentiate MCL from CLL/SLL, based primarily on reported comparisons of immunohistochemical staining of tissue sections. These findings are widely extrapolated to flow cytometric analysis, although available data are contradictory and not sufficiently detailed. We compared expression of CD23 by flow cytometry in 22 cases of MCL and 25 cases of CLL/SLL. Lymphoma cells in 12 of 22 MCLs were negative for CD23, and 10 showed dim expression. In contrast, none of 25 CLL/SLLs were negative for CD23, 4 were dimly positive, and 21 were moderately or brightly positive. Thus, a significant proportion of MCL exhibited overlap of CD23 expression in the low-intensity range with CLL/SLL. Clinically, there was no correlation between the intensity of CD23 expression and clinical stage at diagnosis or survival. These findings emphasize that by flow cytometry, MCL can be differentiated reliably from CLL/SLL using CD23 if negative expression is observed. However, with dimly positive expression, interpretation should be cautious.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11764079     DOI: 10.1309/UQ4N-M5KL-0ANY-YD3G

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  9 in total

1.  A rare case of leukemic presentation of blastoid variant of mantle cell lymphoma with isolated splenic involvement: Flowcytometric revelation.

Authors:  Jyoti Kotwal; Ajay Malik; Vibha Dutta; Vikram Singh; Sandeep Kumar Dahiya; Velu Nair; Rajan Kapoor
Journal:  Med J Armed Forces India       Date:  2013-11-20

2.  Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.

Authors:  John C Byrd; Thomas J Kipps; Ian W Flinn; Januaro Castro; Thomas S Lin; William Wierda; Nyla Heerema; James Woodworth; Steve Hughes; Shabnam Tangri; Sarah Harris; Dee Wynne; Arturo Molina; Bryan Leigh; Susan O'Brien
Journal:  Blood       Date:  2009-10-20       Impact factor: 22.113

3.  Differential and tumor-specific expression of CD160 in B-cell malignancies.

Authors:  Timothy W Farren; Jerome Giustiniani; Feng-Ting Liu; Dimitris A Tsitsikas; Marion G Macey; James D Cavenagh; Heather E Oakervee; David Taussig; Adrian C Newland; Maria Calaminici; Armand Bensussan; Michael Jenner; John G Gribben; Samir G Agrawal
Journal:  Blood       Date:  2011-06-28       Impact factor: 22.113

4.  Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma.

Authors:  Daisy Alapat; Jean Coviello-Malle; Rebecca Owens; Pingping Qu; Bart Barlogie; John D Shaughnessy; Robert B Lorsbach
Journal:  Am J Clin Pathol       Date:  2012-01       Impact factor: 2.493

5.  Flow cytometry as a diagnostic tool in the early diagnosis of aggressive lymphomas mimicking life-threatening infection.

Authors:  Nikolaos J Tsagarakis; Nektaria A Kentrou; Georgios Kakiopoulos; Georgios Androutsos; Athanasios Galanopoulos; Christos Michaelidis; Dimitra Rontogianni; Apostolos Tolis; Stavroula Chini; Georgios Gortzolidis; Konstantinos A Papadimitriou; Dimitra Skoumi; Konstantina Tzanetou; Georgios Paterakis
Journal:  Case Rep Med       Date:  2011-06-05

6.  The Role of CD200 and CD43 Expression in Differential Diagnosis between Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma.

Authors:  Mesude Falay; Berna Afacan Öztürk; Kürşad Güneş; Yasin Kalpakçı; Simten Dağdaş; Funda Ceran; Gülsüm Özet
Journal:  Turk J Haematol       Date:  2017-07-17       Impact factor: 1.831

7.  Fine needle aspiration cytology in the evaluation of lymphoid lesions: a retrospective study of the utility of flow cytometry in conjunction with morphology.

Authors:  Emad M Said Raddaoui; Lubna Sayage-Rabie; Robert S Beissner
Journal:  Ann Saudi Med       Date:  2012 Mar-Apr       Impact factor: 1.526

8.  A new score including CD43 and CD180: Increased diagnostic value for atypical chronic lymphocytic leukemia.

Authors:  Yi Li; Xiwen Tong; Lifang Huang; Li Li; Chunyan Wang; Cheng He; Songya Liu; Zhiqiong Wang; Min Xiao; Xia Mao; Donghua Zhang
Journal:  Cancer Med       Date:  2021-06-01       Impact factor: 4.452

9.  The co-delivery of a low-dose P-glycoprotein inhibitor with doxorubicin sterically stabilized liposomes against breast cancer with low P-glycoprotein expression.

Authors:  Wei Gao; Zhiqiang Lin; Meiwan Chen; Xiucong Yang; Zheng Cui; Xiaofei Zhang; Lan Yuan; Qiang Zhang
Journal:  Int J Nanomedicine       Date:  2014-07-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.